María Eugenia Marín Martínez | Biological Network | Women Researcher Award

Dr. María Eugenia Marín Martínez | Biological Network | Women Researcher Award

Infanta Cristina University Hospital | Spain

Dr. María Eugenia Marín Martínez is a distinguished specialist in Obstetrics and Gynecology with a Bachelor’s degree in Medicine from the University of Valladolid and extensive experience across leading hospitals in Madrid, including Puerta de Hierro Majadahonda University Hospital and Infanta Cristina University Hospital. Dedicated to advancing women’s health at every stage of life, she has been deeply involved in the prevention, diagnosis, and treatment of gynecological conditions. Her professional journey reflects a strong commitment to excellence, having contributed to the development of clinical protocols, particularly during the COVID-19 pandemic, and spearheaded pioneering work in the field of uterine fibroid management through radiofrequency ablation-performing over 200 procedures and establishing her center as a national and international reference. Dr. Marín is pursuing her doctoral thesis on radiofrequency ablation at the Autonomous University of Madrid, with expected defense in 2026. She actively participates in multidisciplinary committees on breastfeeding, gender violence, and chronic pelvic pain, and contributes to humanitarian medical missions in Cameroon. A dedicated educator and researcher, she has authored multiple peer-reviewed publications, book chapters, and clinical guides, while also directing international training courses in gynecological radiofrequency treatment. Through her leadership, innovation, and compassionate care, Dr. Marín continues to play a vital role in advancing obstetric safety, women’s health, and medical education in Spain and beyond.

Profiles: Scopus

Featured Publications

"Transvaginal radiofrequency ablation: a therapeutic option for managing symptomatic uterine fibroids in women with reproductive desires",Maria Eugenia Marin Martinez, F and S Reports, 2024.

Cora Sternberg | Meta analysis | Outstanding Scientist Award

Dr. Cora Sternberg | Meta analysis | Outstanding Scientist Award

Weill Cornell Medicine | United States

Author Profiles

Scopus

Orcid ID

Google Scholar

Early Academic Pursuits

Dr. Cora Sternberg’s academic journey reflects her commitment to excellence from the outset. She completed her medical training with distinction and pursued advanced fellowships, including a Research Fellowship in Immunology at the National Institutes of Health (1976–1977). Her early academic roles as Teaching Assistant at Stanford and Mount Sinai, followed by Clinical Instructor at Cornell University, laid the foundation for her lifelong dedication to education and clinical research. Her Phi Beta Kappa distinction from the University of Pennsylvania marked the start of a career dedicated to innovation and leadership in oncology.

Professional Endeavors

Over four decades, Dr. Sternberg has held prestigious academic and clinical leadership roles. She was Chief of Medical Oncology at San Camillo-Forlanini Hospital in Rome and served as Professor at La Sapienza University, shaping Italy’s oncology community. Since 2018, she has been Professor of Medicine and Clinical Director of the Englander Institute for Precision Medicine at Weill Cornell Medicine and New York-Presbyterian. She has also served as a global faculty member at Temple University, Tufts University, and European institutions.

Contributions and Research Focus

Dr. Sternberg has pioneered groundbreaking research in prostate cancer, bladder cancer, and renal cell carcinoma. She was instrumental in developing practice-changing therapies such as abiraterone, enzalutamide, and darolutamide, significantly improving survival outcomes for prostate cancer patients. Her work in urothelial cancer led to the establishment of M-VAC chemotherapy and global adoption of immunotherapy protocols. She also contributed to the development of pazopanib and other targeted therapies in renal cell carcinoma. Recently, she has expanded her research focus to artificial intelligence in oncology, spearheading initiatives to integrate AI into therapeutic decision-making.

Impact and Influence

With over 546 publications, six textbooks, and more than 45,200 citations, Dr. Sternberg ranks among the World’s Top 2% Scientists (Stanford University) and the top 5% in the Doximity community for citations. She has delivered more than 835 lectures worldwide, influencing clinical practice, policy, and guidelines in oncology. Her leadership roles in international organizations such as ASCO, ESMO, ECCO, and EORTC demonstrate her far-reaching influence.

Academic Citations

Dr. Sternberg’s research impact is widely recognized. Her publications in high-impact journals such as New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology have shaped global treatment standards. Her works are consistently cited in clinical guidelines, trial protocols, and oncology education, affirming her stature as a thought leader in medical oncology.

Legacy and Future Contributions

Dr. Sternberg’s legacy lies not only in transformative research but also in mentorship. She has nurtured generations of oncologists, fostering innovation and translational research. Currently, she co-leads the Career Development Program in the Bladder SPORE initiative, ensuring the pipeline of future oncology leaders. Her pioneering role in AI in oncology positions her to continue shaping the future of precision medicine, bridging clinical care with technological innovation.

Conclusion

Dr. Cora Sternberg exemplifies the qualities of an Outstanding Scientist—visionary leadership, transformative research, global influence, and unwavering dedication to advancing oncology. Her lifelong contributions to clinical practice, groundbreaking research, academic mentorship, and adoption of emerging technologies ensure her lasting impact on the medical community and future generations of scientists.

Notable Publications

"Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100

  • Author: homas Powles; Srikala S. Sridhar; Joaquim Bellmunt; Cora N. Sternberg; Petros Grivas; Ewan Hunter; Matthew Salter; Ryan Powell; Ann Dring; Jayne Green et al.
  • Journal: Cancers
  • Year: 2025

"The Use of Artificial Intelligence for Cancer Therapeutic Decision-Making

  • Author: Olivier Elemento; Sean Khozin; Cora N. Sternberg
  • Journal: NEJM AI
  • Year: 2025

"Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100

  • Author: Thomas Powles; Srikala S. Sridhar; Joaquim Bellmunt; Cora N. Sternberg; Petros Grivas; Ewan Hunter; Matthew Salter; Ryan Powell; Ann Dring; Jayne Green et al.
  • Journal: Preprint
  • Year: 2025

"Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591

  • Author: Scott T. Tagawa; Charlene Thomas; A. Oliver Sartor; Michael Sun; Judith Stangl-Kremser; Mahelia Bissassar; Shankar Vallabhajosula; Sandra Huicochea Castellanos; Jones T. Nauseef; Cora N. Sternberg et al.
  • Journal: Journal of Clinical Oncology
  • Year: 2024

"Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

  • Author: Maha Hussain; Bertrand Tombal; Fred Saad; Karim Fizazi; Cora N. Sternberg; E. David Crawford; Neal Shore; Evgeny Kopyltsov; Arash Rezazadeh Kalebasty; Martin Bögemann et al.
  • Journal: Journal of Clinical Oncology
  • Year: 2023